The detection of PCA3 in the urine has been demonstrated to be a more specific marker to diagnose prostate cancer than the commonly used prostate-specific antigen (PSA) and already found wide application in clinics (Hessels et al., 2003; Tinzl et al., 2004; Lee et al., 2011). This evidence concerns the gene KLK3 and prostate cancer.